Tag Archives: pharmaceutical

European Pharmaceutical Review Launches Their New Media Planner for 2016

The publication European Pharmaceutical Review today announces the official launch of their new media planner for 2016.

Brasted, United Kingdom (November 17, 2015) — The publication European Pharmaceutical Review today announces the official launch of their new media planner for 2016.

“Throughout 2015, we have seen a very successful year unfold, with visitor numbers soaring by more than 230% and website registrations up by more than 78%. These figures show that our audience is becoming more relevant and larger in size to fit our clients’ needs” Graeme Cathie, Publisher, European Pharmaceutical Review.

Responses from their 2015 industry survey confirmed that:
• 95% of their community work in pharma, biotech or academia
• More than 91% of their visitors have influential purchasing power
• They have an online satisfaction rating of over 93%
• Over 78% of their print readers are involved in the decision making process

Each of their print issues goes to the top 25 pharmaceutical and top 25 biotechnology companies as well as the leading 25 life science academic institutions. Now that advertising opportunities are nearly sold out for 2015 both digitally and in print, European Pharmaceutical Review is now selling advertising and sponsorship across its portfolio for 2016.

About European Pharmaceutical Review
European Pharmaceutical Review is the leading publication and website for information on technologies in drug discovery and manufacturing. Published bi-monthly, every issue offers a high level of technical and business contributions from the world’s leading pharmaceutical companies and academic institutions, coupled with a variety of exciting new features including interviews, updates and profiles.

http://www.europeanpharmaceuticalreview.com

For further information, please contact:
Graeme Cathie, Publisher
European Pharmaceutical Review
T: +44 (0)1959 563311
E: gcathie@russellpublishing.com
W: http://www.europeanpharmaceuticalreview.com

AssaysLightning-Link® In-licensing Deal Enhances ImmunoReagents’ Product Offering to the Diagnostic Industry

ImmunoReagents, the global manufacturer of high quality antibody products to the diagnostic and research industry, has entered into a non-exclusive in-licensing deal to use Innova Biosciences (Cambridge, UK) Lightning-Link® technology for commercial purposes.

Cambridge, UK, May 02, 2013 – ImmunoReagents, the global manufacturer of high quality antibody products to the diagnostic and research industry, has entered into a non-exclusive in-licensing deal to use Innova Biosciences (Cambridge, UK) Lightning-Link® technology for commercial purposes.

Through the commercialisation deal, ImmunoReagents will utilise Innova’s technology for the manufacture of antibody conjugates, taking advantage of the very rapid Lightning-Link conjugation protocol that offers 100% yield with enhanced sensitivity in comparison to traditional methods. Such tools are critical to the diagnostic industry; the licensing deal will allow ImmunoReagents to provide enhanced products to facilitate technology development, whilst simultaneously maintaining an effective supply chain when the diagnostic kits are launched into the market place.

Commenting on the agreement ImmunoReagent’s CEO, Dr Ann Black, said, “ImmunoReagents is constantly searching for new technologies to improve our product base and we are pleased to incorporate Innova’s Lighting-Link technology for antibody conjugation.”

Dr Andy Lane, Executive Director at Innova Biosciences, said, “This deal is a perfect example of how Lightning-Link is increasingly being used by high quality manufacturers to both maximise efficiency and increase their product offerings.”

About ImmunoReagents Inc
ImmunoReagents is a leading global manufacturer of quality antibodies and reagents used in research and in vitro diagnostics. They offer a wide range of secondary antibodies covering a broad spectrum of immunoglobulins from various species. ImmunoReagents also provides custom manufacturing to meet specific customer requirements while adhering to cGMP guidelines and ISO quality systems requirements. The Company is located on NCSU’s Centennial Campus, a 1000 acre advanced technology community for university, government and industrial partners. For more information, please see www.immunoreagents.com.

About Innova Biosciences Limited
Innova Biosciences is a growing, dynamic, ISO 9001:2008 business based in Cambridge, UK. At the core of Innova’s business are the Lightning-Link®, InnovaCoat® and Thunder-Link® technologies, which simplify the production of antibody-based reagents. The expanding portfolio is sold to research laboratories, pharmaceutical companies, biotechnology companies and diagnostic companies worldwide. Innova Biosciences invites anyone with an interest in antibody labeling, flow cytometry, lateral flow assays or any lightning link products to please visit the website at http://www.innovabiosciences.com.

Contact:
Mathew Taylor
Director
Algorythm Solutions Ltd
10 Torkington St, Stamford
Lincolnshire PE9 2UY
+44 (0)773 403 2112
mtaylor@algorythmsolutions.com
http://www.algorythmsolutions.com

Innovative Drug Discovery Business, Biosortia Pharmaceuticals, Lands Two Health Care Veterans

Kurt Dieck formerly SVP of Strategy and Business Execution at Cardinal Health, will lead early stage drug discovery business at Biosortia Pharmaceuticals. Dieck was named President and CEO in November 2012 and has quickly identified other key executives, including Dr. Guy Carter, former Natural Product head at Wyeth Pharmaceuticals, as his Chief Science Officer. In conjunction, other collaboration partners have joined the team, including NOAA (National Oceanic and Atmospheric Administration), NCI (National Cancer Institute) and key universities, to strategically accelerate the development of novel drug leads in the therapeutic areas of cancer, infectious diseases, inflammation and neurological disorders. Biosortia Pharmaceuticals has seen promising early results with dozens of novel compounds having already been requested, and are under evaluation with NCI and Eli Lilly.

Dieck has spent nearly 30 years in healthcare, including 18 years at Arthur Andersen as a global equity partner and then 10 years with Cardinal Health, a Fortune 20 public company, as a senior executive; there he worked with a broad spectrum of partners, including brand pharmaceutical manufacturers, throughout the supply chain. Dr. Guy Carter has over 30 years of experience working in pharmaceutical R&D, primarily in the discovery and development of microbial natural products. He previously was the leader of natural products drug discovery at Wyeth Research, as head of the Chemical Technologies Department.

“Kurt and Guy make a great team. Their complementary Pharma experiences and backgrounds create great opportunities to accelerate Biosortia’s objective to become the premier, aquatic natural products company with a primary focus in drug discovery,” says Ross Youngs, Biosortia’s Founder and Chairman. “Kurt and Guy bring a wealth of research and business experience along with deep industry relationships in building successful Pharma partnerships. Everyone involved with this young biotech is excited about the future.”

Industry observers have commented that late-stage R&D pipelines are not providing Pharma with the desired revenue growth the market is expecting. Therefore, large Pharma is evolving the way it performs R&D in order to optimize efficiency and to boost patent cliff defenses. These changes require shifting from relying solely on in-house chemistry-based R&D to acquiring and licensing external technologies and natural products based compounds in various stages of development. Biosortia’s ability to supply novel, highly active and potent compounds with drug-like characteristics will increase the productivity and success rate for Pharma as well as reduce the overall cost of the discovery process. The cost to discover, develop and launch a new drug is estimated to reach nearly $3B per drug by 2015. Biosortia’s business model is designed specifically to support Pharma’s needs.

“With nearly unlimited microorganisms (3.7 nonillion), the aquatic environment and its consortia represent an extraordinary opportunity…a new frontier, to access extremely potent and chemically diverse secondary metabolites with drug-like properties with unique mechanisms of action never researched before,” said Dieck. In describing the opportunity, Dieck goes on to say, “Biosortia is on the cutting edge of natural product discovery
and has the capabilities to deliver on its aspiration. Our powerful natural products research team, led by Dr. Guy Carter, in partnership with NOAA’s Dr. Peter Moeller, a leader in aquatic natural products research, has the experience and know-how to decipher the complex unexplored environment in a very efficient manner leveraging all the current state of the art instrumentation. The need for more efficient and effective approaches to drug discovery has never been more important. Biosortia’s innovative technologies, deep research skills and key relationships will efficiently provide thousands of unique natural products as candidates for drug discovery at a time when Pharma is in critical need for “high quality shots on goal.”

“Aquatic microbial consortia are a rich source of metabolically active organisms including microalgae, bacteria, fungi and their secondary metabolites,” states Carter. “Owing to the competitive nature of their habitat, chemical investigations of microbial consortia reveal unique structurally diversified natural products that are responsible for signaling and self-defense that have potential as therapeutics with novel mechanisms of action. Since they have been pre-optimized by nature, these compounds are typically closer to a drug candidate than a synthetic lead, thus requiring less optimization and shorter time when found as ‘hits’ in screening programs.”

The team has also focused on agreements with strategic collaboration partners as vital components to the strategy. Biosortia has recently entered into several collaboration agreements with NOAA, Analyticon and exclusive harvesting relationships, just to name a few. Several others will be advanced by the end of January. Biosortia’s cooperative research and development agreement (CRADA) with NOAA’s Center for Human Health Risk at Hollings Marine Laboratory provides a 5-year framework for research and development regarding the analysis and purification of novel bioactive compounds. According to NOAA’s Technology Partnerships Office, “Success will result in the commercial development of new and unique chemical compounds from the sea which have benefits to human health, either through disease prevention or new treatments for disease.”

Dr. Peter Moeller, NOAA’s Research Scientist who leads the Toxins Natural Products Program stated after analyzing fractions of Biosortia’s biomass, “Coupling NOAA’s mission of characterizing toxins affecting environmental and/or human health with Biosortia’s drug discovery focus turns one man’s toxin into another’s chemotherapeutic. The microorganisms analyzed in the Biosortia biomass identified more unique activity than I have seen in my 30 year career. The volumes achieved from a single harvest delivered an equivalent of 30 years of accumulation. This could materially change the landscape for natural products drug discovery research.”

As of December 31, 2012, Biosortia has identified more than 30 bioactive candidate compounds (hits) from a fresh water eutrophic lake consortium. Therapeutic areas of focus include treatments for cancer, infectious diseases, inflammation and neurological disorders. In addition, more than a dozen of its patent protected compounds are in initial evaluation stage within Eli Lilly’s Open Innovation Drug Discovery Program.

Dieck states, “Looking forward, it is with great optimism. We have a great team built around mutual respect, deep experience, and a desire to succeed and make a difference. We are aligning with the right partners and collaborators to execute our strategy with speed and discipline to provide Pharma with much high quality & diverse compounds vs. “me-too” drugs than they have had in the past 10 years. We are excited about what this company can accomplish, not only for its shareholders but also for the millions of people who have been diagnosed with various forms of chronic diseases who are looking for Pharma to identify better ways to help them extend their lives or live a more productive life. Biosortia can play a big role in identifying compounds that can help Pharma achieve these goals. I am looking forward to the challenge and opportunity to build an industry leading drug discovery company.”

# # #

About Biosortia Pharmaceuticals http://www.biosortia.com/: Biosortia Pharmaceuticals is a division of Algaeventure Systems (AVS). AVS is privately held company and are the inventors of the biomass harvesting technology. Biosortia has a proven and unique ability to obtain unculturable aquatic microorganism consortia from the natural environment in unprecedented quantities that allows its research team to perform direct study of vast quantities of new natural products (NPs), the foundation of most anti-infective agents such as antibiotics for the treatment of bacterial infections. Over 76% of cancer drugs are derived in some manner from NP.

If you’d like more information about the announcement or the company or to schedule an interview with Kurt Dieck, please call:

David Coho
Tel. 614-636-4850
Cell Phone: 614-325-9804
Email: dcoho@biosortia.com

 

Molplex and Enamine Announce a New Partnership

Newcastle, UK and Kiev, Ukraine. January 24th 2010 – Molplex and Enamine today announced a new partnership to offer the Enamine screening collection of 1.8 million stock chemicals through the Molplex online drug design and assay-ready chemical supply services. The agreement is a major step towards eliminating the high start-up costs ofdrug discovery, bringing sophisticated drug design, compound management and assay-ready chemistry to the world’s drug discovery scientists on demand. The agreement adds Molplex online drug design systems to the deep experience in organic chemistry and compound management of Enamine to solve the problem of generating viable chemical leads for novel targets.

Molplex CEO David E. Leahy said: “We are very proud to be selected by Enamine as their partner for on demand drug discovery services at a time when major restructuring of the industry is creating new opportunities and new markets for our combined expertise. This agreement marks a step change in the size and scope of our assay-ready chemical supply service and major progress towards our goal of being the world’s first choice partner for enabling the long tail of drug discovery”

Enamine Chief Marketing and Sales Officer Dr Vladimir Ivanov said “We are happy to partner with Molplex and supply our products to the highly integrated drug discovery platform they maintain. In this collaboration we deploy all our discovery resources including the world’s biggest screening collection (1.8 million compounds), largest inventory of building blocks (45,000 products), and over 300 chemists at our Kiev’s site to assure high cost efficiency and high responsiveness to any follow up chemistry emerging from projects run through Molplex discovery platform.”

About Molplex
Molplex was created by David Leahy and Vladimir Sykora to help anyone anywhere in the world invent new medicines. Molplex’s ambition is to eliminate the high set up costs of drug discovery providing the sophisticated online drug design systems integrated with assay ready chemical supply and high content screening. CEO David Leahy previously founded Cyprotex PLC, now the world’s largest ADME Tox service supplier. The Molplex team offers extensive drug discovery experience and sophisticated software systems for automated drug design. Molplex goal is to enable the long tail of drug discovery to provide the new medicines of tomorrow by eliminating the cost of entry and increasing success rate of drug discovery projects

For more information visit www.molplex.com.

About Enamine
Enamine has been established as a provider of research services to the pharmaceutical and biotechnology industry since 1991 and is the world’s largest chemistry supplier of innovative compound libraries and building blocks to the pharmaceutical industry.

For more information on Enamine visit www.enamine.net

Contact Details:

David Leahy, CEO,
Molplex Ltd.
i6 Charlotte Square
Newcastle Upon Tyne
England, NE1 4XF
info@molplex.com
Tel: US: 1-408-905-2900
Europe : 44-191-211-196
Dr Vladimir Ivanov, Chief Marketing and Sales Officer
ENAMINE Ltd.
23 Alexandra Matrosova Street
01103 Kiev, Ukraine
v.ivanov@enamine.net
Tel: +38 044 537 32 18
Fax: +38 044 537 32 53